Search results
Columbia Scientists Unravel a 15-Year Mistake in Stem Cell Research
SciTechDaily· 6 hours agoColumbia University’s research has uncovered a longstanding error in identifying gut stem cells,...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 15 hours agoIndia Breakthrough: Bio Regenerative Precision Medicine Seminar Held in Hyderabad PR Newswire HYDERABAD, India, June 10, 2024 HYDERABAD, India, June 10, 2024 /PRNewswire/ ...
Octane Medical acquires B. Braun’s global orthobiologics business
Digital Journal· 3 days agoOctane Medical Group, through its new venture Octane Biotherapeutics (BioTx), has acquired 100% shares of the global orthobiologics business from its long-term partner B. Braun. The acquisition ...
FibroBiologics Shares Up 38% on Withdrawn Equity Offering
Market Watch· 4 days agoFibroBiologics shares rose Thursday after the cell therapy and regenerative medicine company said it will no longer pursue a planned equity offering. The ...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 7 hours agoCell & Gene Therapy Supply Chain Software Market Expected to Grow at a 13.9% CAGR from 2024-2031 | Latest Report by InsightAce Analytic PR Newswire JERSEY CITY, N.J., June ...
Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why
Zacks via Yahoo Finance· 5 days agoAn update on the clinical study is expected in the third quarter of 2024. Apart from these, Ocugen’s...
Nava Health Announces Lease Signing for First New York Location
Digital Journal· 5 hours agoScott Kamelle Presents Over a Decade of Expertise in HIPEC Therapy for Ovarian Cancer Patients Grace Pettis Releases Soulfully Optimistic Single 'Joy' Ahead of New Album Prysmian ...
Greater Boston’s last remaining salt marsh is in danger. Again. - The Boston Globe
The Boston Globe· 1 day agoA volunteer-led group of residents — the Friends of Belle Isle Marsh — have fought for the area’s...
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders
Digital Journal· 6 days agoNurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies ...
These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now
Motley Fool via Yahoo Finance· 2 days agoThe program already has a handful of regulatory designations that'll move the process along,...
